Format

Send to

Choose Destination
Pharmacogenomics. 2014 Dec;15(16):1973-83. doi: 10.2217/pgs.14.153.

Genotype and risk of major bleeding during warfarin treatment.

Author information

1
Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA.

Abstract

AIM:

To determine whether genetic variants associated with warfarin dose variability were associated with increased risk of major bleeding during warfarin therapy.

MATERIALS & METHODS:

Using Vanderbilt's DNA biobank we compared the prevalence of CYP2C9, VKORC1 and CYP4F2 variants in 250 cases with major bleeding and 259 controls during warfarin therapy.

RESULTS:

CYP2C9*3 was the only allele that differed significantly among cases (14.2%) and controls (7.8%; p = 0.022). In the 214 (85.6%) cases with a major bleed 30 or more days after warfarin initiation, CYP2C9*3 was the only variant associated with bleeding (adjusted odds ratio: 2.05; 95% CI: 1.04, 4.04).

CONCLUSION:

The CYP2C9*3 allele may double the risk of major bleeding among patients taking warfarin for 30 or more days.

KEYWORDS:

CYP2C9; CYP4F2; VKORC1; pharmacogenetics; risk of major bleeding; warfarin

PMID:
25521356
PMCID:
PMC4304738
DOI:
10.2217/pgs.14.153
[Indexed for MEDLINE]
Free PMC Article

Publication types, MeSH terms, Substances, Grant support

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center